Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kangxinning is a Chinese patent medicine developed by the Inner Mongolia Autonomous Region Pharmaceutical Industry Research Institute Co., Ltd., primarily indicated for the treatment of coronary heart disease and angina pectoris. Formulated typically as a capsule, it contains a combination of Traditional Chinese Medicine (TCM) extracts, including *Salvia miltiorrhiza* (Danshen), *Panax notoginseng* (Sanqi), *Dalbergia odorifera* (Jiangxiang), and *Borneolum syntheticum* (Bingpian). The drug exerts its therapeutic effects by promoting blood circulation, resolving blood stasis, and dilating coronary arteries, which improves myocardial blood supply and reduces oxygen consumption. It is clinically used to relieve symptoms such as chest pain, palpitations, and shortness of breath associated with cardiovascular stasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kangxinning.